PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Mometasone furoate - Allergic rhinitis

PAD Profile : Mometasone furoate - Allergic rhinitis

Keywords :
Hay fever, hayfever, antihistamines, nasal sprays, allergy, seasonal allergic rhinitis, pollen allergy, intranasal corticosteroids, INCS
Brand Names Include :
Nasonex

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Important
Formulations :
  • Nasal spray
Important Information :
Beclometasone (200 dose container) is the preferred intranasal steroid for allergic rhinitis. Mometasone is 2nd line, once daily.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Guidelines (Local)
01 January 2024

Committee Recommendations

Date
Committee Name
Narrative
05 April 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Generic mometasone furoate (once daily) nasal spray was agreed as a 1st line treatment option for intranasal corticosteroids.
Generic beclometasone or Beconase nasal spray (200 dose container) is an appropriate 1st line alternative.

Consider mometasone if an intranasal corticosteroid is required for short term use due to systemic absorption (6-18years).

Associated BNF Codes

12. Ear, Nose and Oropharynx
12.02.01. Drugs used in nasal allergy
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More